Feasibility and efficacy of gemcitabine plus albumin-bound paclitaxel combination therapy (GEM+nabPTX therapy) in patients with borderline resectable pancreatic cancer in the neoadjvant setting.

Feasibility and efficacy of gemcitabine plus albumin-bound paclitaxel combination therapy (GEM+nabPTX therapy) in patients with borderline resectable pancreatic cancer in the neoadjvant setting. - Feasibility and efficacy of GEM+nabPTX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022000

Enrollment

Registered

2016-04-20

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline resectable pancreatic cancer

Interventions

Neoadjuvant chemotherapy with GEM+nabPTX therapy followed by surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) invasive ductal carcinoma of the pancreas 2) no distant metastasis 3) R0/1 resectable 4) borderline resectable Pancreatic cancer 5) all adult who anticipate to undergo pancreatectomy 6) no prior therapy 7) ECOG performance status of 0 or 1 8) adequate organ function 9) oral intake is possible 10) written informed consent

Exclusion criteria

Exclusion criteria: 1) pulmonary fibrosis or interstitial pneumonitis 2) Active double cancer 3) Active infection 4) HBs antigen positive 5) patients are using flucytosine, phenytoin, warfarin 6) pregnant females, possibly pregnant females

Design outcomes

Primary

Measure	Time frame
R0 resection rate	—

Countries

Japan

Contacts

Public ContactFumiaki Ozawa

Saitama Medical Center, Saitama Medical University Department of Hepatobiliary Pancreatic Surgery

ozawa2@hotmail.com049-228-3400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026